Antisense Oligonucleotides Market
Antisense Oligonucleotides Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Antisense Oligonucleotides Market Size and Growth
The Antisense Oligonucleotides market is poised for significant growth, driven by advancements in personalized medicine and rising prevalence of genetic disorders. The market size is estimated to reach approximately $2.2 billion by 2026, reflecting a compound annual growth rate (CAGR) of around 15%, fueled by increasing R&D investments and therapeutic applications.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Ionis Pharmaceuticals
◍ Sarepta Therapeutics
◍ Biogen
◍ Alnylam Pharmaceuticals
◍ Antisense Therapeutics
◍ Isarna Therapeutics
◍ Arrowhead Pharmaceuticals
◍ Atlantic Pharmaceuticals
◍ Enzon Pharmaceuticals
◍ Bio-Path Holdings
◍ GlaxoSmithKline
◍ Geron
◍ ICO Therapeutics
◍ Marina Biotech
◍ RXi Pharmaceuticals
The Antisense Oligonucleotides Market features key players like Ionis Pharmaceuticals and Sarepta Therapeutics, driving innovation and development. Companies such as Alnylam and Biogen advance therapeutics, while others like Arrowhead and Marina Biotech enhance applications. Their collaboration fuels market growth, leveraging targeted therapies for various diseases.
- Ionis Pharmaceuticals: $1.09 billion (2022)
- Biogen: $8.3 billion (2022)
- Alnylam Pharmaceuticals: $1.2 billion (2022)
Request Sample Report
Market Segmentation
By Application
Hospitals
Clinic
Others
By
Product
◍ RNA Antisense Oligonucleotides
DNA Antisense Oligonucleotides
Request Sample Report
$ 235.75 Billion
Request Sample Report
